A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U

Trial Profile

A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms HOVON 130 NHL
  • Most Recent Events

    • 13 Jul 2017 Planned number of patients changed from 72 to 85.
    • 17 Aug 2015 New source identified and integrated (Netherland Trials Register:NTR5267 )
    • 11 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top